Kalohexis Shares 710GO Data Supporting Durable Weight Loss
NORTHBROOK, Ill., July 15, 2026 Kalohexis, Inc., a clinical-stage biotechnology company developing innovative therapies for metabolic diseases, has unveiled...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
NORTHBROOK, Ill., July 15, 2026 Kalohexis, Inc., a clinical-stage biotechnology company developing innovative therapies for metabolic diseases, has unveiled...
BOSTON, June 15, 2026 Bambusa Therapeutics has announced positive preliminary multiple ascending dose (MAD) Phase 1 clinical data for...
BOSTON, June 15, 2026 Bambusa Therapeutics has announced positive preliminary results from the multiple ascending dose (MAD) cohorts of...
LONDON, UK — March 30, 2026 In a major advancement in respiratory medicine and biologic drug innovation, GSK plc...
